Corbus Pharmaceuticals Holdings, Inc. (CRBP) Social Stream
Featured Post From StockTwits About CRBP
$CRBP “The primary endpoint of the study was met, with a significantly higher proportion of responders in the octagam® 10% group compared with the placebo group (78.7% vs 43.8%; p=0.0008)fezziwig2019, published November 22, 2020
The response in the octagam® 10% group in the First Period of the study was maintained for all efficacy endpoints through the open-label Extension Period
The majority of adverse events were mild in intensity and octagam® 10% was generally well tolerated in this population of patients with dermatomyositis.”
Wow - 1st a positive Phase 3 Dermatomyositis study - while $CRBP fails in easier targets while promising same.
(no position - out with profit- just checking in on 5% bogus bump)